Humana Inc. (HUM) is forming a joint venture with BlackRock's HPS Investment Partners to own nearly 150 CenterWell Senior Primary Care clinics. BlackRock will acquire the existing equity stake valued at approximately $2.8 billion and hold majority ownership, while CenterWell retains minority ownership and operational control. The partnership is expected to reduce Humana's balance sheet liabilities, provide greater financial flexibility, and accelerate clinic expansion. The transaction is set to close in Q4 2026 without materially affecting 2026 earnings guidance.

UnitedHealth Group reported Q3 2026 earnings of $4.69 per share, beating consensus estimates of $4.12 and representing a 13.84% surprise. The company posted revenues of $112.69 billion, slightly exceeding expectations. With a Zacks Rank #2 (Buy) rating, UnitedHealth has outperformed the S&P 500 by 0.6% year-to-date. However, the Medical - HMOs industry ranks in the bottom 24% of Zacks industries, which could impact future performance.

Humana shares surged 11.6% to $431.87, driven by strong Medicare membership growth (up 20.7% YoY to 17.9 million members) and expansion of its CenterWell platform. However, the stock faces headwinds as consensus EPS estimates have been revised 2.7% lower over the past 30 days, and the company is expected to report a quarterly loss of $1.04 per share. The stock holds a Zacks Rank #3 (Hold) rating.

UnitedHealth Group (UNH) and Humana (HUM) are compared as major players in U.S. managed healthcare. UNH benefits from its diversified Optum platform, improving Medicare Advantage profitability, and $1.5B AI investments, while HUM shows strong Medicare Advantage membership growth of 23.8% but faces margin pressures from rising benefit costs. UNH is rated as the more compelling investment with a Zacks Rank #2 (Buy) versus HUM's Rank #3 (Hold), offering 28.1% upside potential compared to HUM's 7.7%.

UnitedHealth Group is expected to report Q3 2026 earnings on October 13, 2026, with projected EPS growth of 41.1% to $4.12 per share, despite a 1.6% revenue decline to $111.38 billion. The company faces headwinds from declining memberships across commercial, Medicare Advantage, and Medicaid segments, but improved medical cost management and operational restructuring are expected to support margin expansion. UnitedHealth trades below its historical valuation median at 17.15X forward earnings, positioning it for potential recovery.

UnitedHealth Group heads into Q3 earnings with focus on whether its Q2 medical cost improvements can be sustained. The company improved its medical cost ratio to 86.7% in Q2, though $860 million in favorable reserve development aided results. Key questions include whether underlying medical costs remain stable and whether UnitedHealth can improve Medicare Advantage margins while managing expected membership losses of roughly 1.1 million members in 2025.

Centene Corporation is restructuring its Medicare Advantage business for 2027, pulling standard MA plans from 344 counties and exiting Hawaii, Oklahoma, and Tennessee due to unfavorable economics. The company is shifting focus toward Special Needs Plans and dual-eligible members while leveraging its Part D platform. Competitors UnitedHealth and Humana are also refining their MA footprints with similar selective approaches as medical and pharmacy costs pressure plan profitability.

OneTrust announced the winners of its 2026 TrustMaker Awards at TrustWeek, recognizing organizations excelling in responsible AI governance and data use. Fiserv, Workday, Humana, and Rockwell Automation were honored for their achievements in AI governance, operational excellence, impact, and overall trust leadership respectively. OneTrust also unveiled CORIE, a new platform innovation designed to govern AI agents at enterprise scale.

Dr. Aaron L. Schwartz, an assistant professor at the University of Pennsylvania, has been awarded the 2026 AJMC Seema S. Sonnad Emerging Leader in Managed Care Research Award for his groundbreaking work on low-value care metrics and prior authorization research. His claims-based measures have been adopted by CMS for accountable care programs, and his research has influenced policy decisions at major healthcare organizations and government agencies.

Centene Corporation reported Q2 2026 adjusted EPS of $2.51, marking a significant recovery from a loss a year prior, driven by improved medical cost trends and better execution. The company expects Medicaid membership to decline 8%-9% in 2026, but profitability improvements in Marketplace and Medicare segments, combined with higher Medicaid rates and cost initiatives, support continued recovery. CNC reaffirmed its 2026 adjusted EPS guidance above $4.80.

The value-based healthcare market is experiencing robust growth, projected to reach USD 62 billion by 2034 from USD 16.5 billion in 2025, with a CAGR of ~16%. The shift from fee-for-service to outcome-based payment models is driven by rising healthcare costs, chronic disease burden, and government reimbursement reforms. North America dominates with 72% market share, while Asia-Pacific is expected to record the fastest growth. Key players include Optum, Humana, Evolent Health, Agilon Health, and Privia Health.

The Invesco S&P 500 Pure Value ETF (RPV) is a smart beta ETF with $1.75 billion in assets that tracks the S&P 500 Pure Value Index. It has delivered 19.31% year-to-date returns and 26.47% over the past year with a 0.35% expense ratio. The fund holds 125 stocks with heavy exposure to Financials (20.4%), Healthcare, and Consumer Staples sectors. While RPV offers reasonable value-focused exposure, cheaper alternatives like Vanguard's VTV (0.03% expense ratio) and Schwab's SCHD (0.06% expense ratio) may be more cost-effective for investors.